Testing ALN-APP for cerebral amyloid angiopathy
Part of Brain & nervous system, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests an experimental medicine called ALN-APP for people with a condition called cerebral amyloid angiopathy (CAA) — a buildup of protein in brain blood vessels that can cause bleeding. The drug aims to reduce this protein and possibly prevent future strokes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 50 years old (for sporadic CAA) or at least 30 years old (for Dutch-type CAA).
- You have probable CAA according to the Boston Criteria or a known genetic mutation for Dutch-type CAA.
- You have not had a recent (within the last 90 days) bleeding stroke.
- You do not have moderate or severe Alzheimer's disease or other significant cognitive problems.
- Your liver and kidney function tests meet safety limits (tests done at screening).
- You have not received an experimental treatment or amyloid-targeting antibody recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the drug LXB (sodium oxybate) can help clear abnormal protein buildup in the brain's small blood vessels (CAA). Participants will take LXB nightly for 8 weeks and have MRIs and spinal taps to measure changes.
This Phase 2 study tests AMDX-2011P to see if it can help people with cerebral amyloid angiopathy (CAA), a condition where abnormal protein affects blood vessels in the brain. You may be able to join if you have confirmed or likely CAA and a recent brain MRI showing changes from CAA.
This study looks at brain MRI scans in people with cerebral amyloid angiopathy (a condition where amyloid builds up in brain blood vessels). The goal is to search for “biomarkers,” or measurable scan features, to better understand and detect the disease in some people before symptoms or during symptoms.
This trial tests a traditional Chinese medicine called Jiedu Huayu to see if it helps people recover from a brain bleed caused by a condition where proteins build up in blood vessel walls (cerebral amyloid angiopathy). The goal is to improve outcomes without surgery.
This trial tests if colchicine can reduce the risk of another stroke caused by bleeding in the brain due to a condition called cerebral amyloid angiopathy (CAA). You may qualify if you've recently had a brain bleed from CAA and have certain signs on brain scans.
This trial is looking at how brain “small blood vessel disease” changes over time and what outcomes to expect. If you have certain symptoms or scan findings from this condition, your care team may compare your prognosis to help guide future treatment planning.
Hear when a new Cerebral Amyloid Angiopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.